Abstract 17479: Continuous Statin Treatment Improves Mid-term Outcomes of Patients with Elevated C Reactive Protein after Coronary Artery Bypass Grafting Surgery
Background: This study aims to assess the effect of postoperative statin therapy on patients undergoing coronary artery bypass grafting surgery (CABG).
Methods and Results: This study included 2837 patients from Chinese Coronary Artery Bypass Grafting Registry Study undergone isolated CABG and survived to discharge between January 2006 and December 2007 in Fuwai Hospital. Those patients were divided into two groups: a low inflammatory status (LIS) group of 1783 patients with hsCRP levels ≤ 2.5 mg/L, and a high inflammatory status (HIS) group of 1054 patients with hsCRP levels >2.5 mg/L. Follow-up lasted a maximum of 3.6 years (median 1.7 ± 0.6 years) and was 99.6% complete. Continuous statin therapy was defined as taking statins as prescribed 80% of the time or more. For the HIS group, continuous statin therapy had lower mortality (0.74% vs. 5.28%; p<0.001), less MACE (3.31% vs. 7.05%,p=0.003) and lower incidence of heart failure (2.03% vs. 4.89%, p=0.01) compared with those did not take persistent statins. The Cox proportional hazards model showed that continuous statin therapy remarkably reduced risk of mid-term mortality (HR 0.36, 95%CI 0.25-0.70, p=0.002), MACE (HR 0.46, 95%CI 0.25-0.82, p=0.01) and incidence of heart failure (HR 0.31, 95%CI 0.14-0.66. p=0.003). However, for the LIS group, continuous statin therapy did not show protective effect for mid-term outcomes.
Conclusions: Postoperative continuous statin therapy was associated with reduced mid-term mortality, incidences of MACE and heart failure for patients with elevated preoperative levels of hsCRP.
- © 2010 by American Heart Association, Inc.